Baird downgraded Quest Diagnostics (DGX) to Neutral from Outperform with an unchanged price target of $194. The firm believes the stock’s risk/reward at current levels is too balanced following the recent rally to stay positive. Baird is bullish on Quest’s fundamentals, citing valuation for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target lowered to $190 from $200 at Piper Sandler
- Quest Diagnostics: Strong Volume Growth and Strategic Partnerships Drive Buy Rating
- Quest Diagnostics price target raised to $185 from $180 at Evercore ISI
- Quest Diagnostics price target raised to $191 from $182 at Morgan Stanley
- Quest Diagnostics price target raised to $180 from $175 at UBS